Pregabalin in the management of partial epilepsy by Arain, Amir M
© 2009 Arain, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2009:5 407–413
Neuropsychiatric Disease and Treatment
407
E x P E rT   O P i N i O N
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Pregabalin in the management of partial epilepsy
Amir M Arain
Vanderbilt University Medical Center, 
Department of Neurology, Nashville, 
TN, USA
Correspondence:   Amir M Arain  
A-0118 Medical Center North,  
Nashville TN 37232, USA 
Tel +1 (615) 936–2591 
Fax +1 (615) 936–0223 
Email amir.arain@vanderbilt.edu
Abstract: Pregabalin is a new antiepileptic medication that works by binding to alpha 2 delta 
subunit of the voltage-dependent calcium channels present in presynaptic neurons. Its pharmaco-
kinetic advantages include rapid and almost complete absorption, lack of protein binding, linear 
kinetics, absence of enzyme induction, and absence of interactions with other drugs. Pregabalin 
was found effective as adjunctive therapy for refractory partial-onset seizures, with up to 51% 
responder at a dose of 600 mg/day. The lowest effective dose was 150 mg/day. Pregabalin is 
also approved for treatment of painful diabetic polyneuropathy, postherpetic neuralgia and pain 
with fibromyalgia. Studies also suggest a beneficial effect on sleep and generalized anxiety 
disorders. Its main adverse effects in randomized adjunctive trials in adults have been mild to 
moderate. Most common side effects were dizziness, ataxia, somnolence and diplopia. Weight 
gain was not prominent in pivotal pregabalin trials, but was more problematic in long-term 
postmarketing analyses in epilepsy patients. Pregabalin, with its potent antiseizure effect, 
favorable pharmacokinetic profile, and effectiveness in common co-morbidities is an important 
addition to the treatment of epilepsy.
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Epilepsy is a common chronic neurological disorder that affects 0.5% to 1% of the 
population,1 and presents with recurrent unprovoked epileptic seizures. Surgical treatment 
may be curative in selected patients but overall there is no curative therapy for all epilepsy 
patients, and therapy is usually directed to prevention of seizures with antiepileptic drugs 
(AEDs). The management of epilepsy should be geared towards complete control of 
seizures while minimizing the occurrence of adverse events and improving the patient’s 
quality of life.2 Approximately two thirds of patients become seizure-free with AED therapy, 
leaving the remaining third with persistent seizures.3 Patients may have to take AEDs for 
the rest of their life. Thus there is a need for newer and better-tolerated AEDs.
Before 1993 a limited number of AEDs were available. A variety of antiepileptic drugs 
have been introduced over the last 15 years. All of the newer AEDs have been shown 
to be effective as adjunctive agents in partial epilepsy. Marson et al’s meta-analysis has 
shown that the response and tolerability of new AEDs in patients with refractory epilepsy 
are similar. Each drug was significantly better than placebo at preventing seizures.4
Pregabalin is the latest addition in the antiepileptic medication regimen in the United 
States. It was approved by Food and Drug Administration in 2005 as an add-on therapy 
for partial epilepsy, for painful diabetic polyneuropathy, postherpetic neuralgia, and 
fibromyalgia.Neuropsychiatric Disease and Treatment 2009:5 408
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Mechanism of action
Pregabalin was designed to be an analogue of GABA, but it 
does not act at GABA receptors.5 Pregabalin does not act on 
sodium channels, potassium channels, or glutamate receptors. 
Like gabapentin it works by binding to alpha 2 delta subunit 
of the P/Q-type voltage-sensitive Ca2+ channels (VSCC) 
which are present in presynaptic neurons.6,7 It does not block 
calcium channels rather it modulates calcium channels.6 In 
various animal models pregabalin exhibits anticonvulsant, 
anxiolytic and analgesic properties.5
Pharmacology
Pregabalin is rapidly and completely absorbed after oral 
dosing in the fasting state (bioavailability is 90%). 
Its absorption is not dose-dependent. Maximal plasma 
concentrations are reached in 1 hour after single or multiple 
doses, and steady state is achieved within 24 to 48 hours after 
repeated administration. Therefore, pregabalin can be taken 
with or without food. The pharmacokinetics of pregabalin 
is linear and predictable across the therapeutic dosage range 
(150 to 600 mg/day). Pregabalin has a plasma half-life of 6.3 
hours. It has to be given in 2 or 3 divided doses. It reaches 
steady-state plasma levels within 1 or 2 days of dosing.
Pregabalin is not protein bound and is excreted virtually 
unchanged by the kidneys. AEDs by the virtue of their 
protein binding and hepatic metabolism commonly results 
in important drug interactions that can have life-threatening 
clinical consequences.8 Pregabalin does not go through any 
significant hepatic metabolism. Pregabalin does not inhibit or 
induce hepatic enzymes. These properties enable it to cause 
no significant interactions with concomitant medications, 
eg, oral contraceptives.9,10As was evident in a study of 
patients with refractory partial seizures in open-label, 
multiple-dose study with pregabalin 600 mg/day, given as 
200 mg 3 times a day for 7 days, in addition to maintenance 
monotherapy with valproate (VPA), phenytoin (PHT), 
lamotrigine (LTG), or carbamazepine (CBZ). The baseline 
antiepileptic medications were unaffected by concomitant 
pregabalin administration.11 However in another study 
pregabalin level decreased by 20% to 30% in the presence of 
enzyme-inducing antiepileptic drugs (eg, carbamazepine).12 
Because pregabalin is excreted mostly unchanged 
through kidney, there is less need for therapeutic drug 
monitoring. However drug monitoring may be useful 
based on intra-individual comparisons of drug serum 
concentrations.13 Its excretion is proportional to creatinine 
clearance. In patients with renal insufficiency pregabalin 
dose has to be adjusted according to the creatinine clearance 
if lower than 60 mL/min. A 50% reduction in pregabalin 
daily dose is recommended for patients with creatinine 
clearance between 30 and 60 mL/min. Pregabalin daily 
doses should be further reduced by approximately 50% for 
each additional 50% decrease in creatinine clearance, as 
noted by Randinitis et al.14
Pregabalin clinical trials
Pregabalin’s efficacy and safety have been studied in patient 
with partial epilepsy, with or without secondary generalization 
as an add-on therapy. Pregabalin was studied in 4 randomized, 
double-blind, placebo-controlled trials (Table 1).
French et al studied pregabalin’s efficacy, safety, and 
tolerability in patients with partial seizures and to confirm 
the dose-response relationship. In this multicenter, double-
blind, randomized, placebo-controlled, parallel-group study, 
patients were given pregabalin in 2 divided doses over a 
12-week double-blind phase.15
Patients with refractory partial seizures on 1 to 3 
antiepileptic drugs were randomized to one of the five 
treatment groups (placebo or 50, 150, 300, and 600 mg/day 
pregabalin, all administered twice daily). The intent-to-treat 
analysis included 453 patients. Seizure frequency reductions 
from baseline analyses showed 7% in the placebo group, 12% 
in the 50 mg/day arm, 34% in the 150 mg/day arm, 44% in 
the 300 mg/day arm, and 54% in 600 mg/day arm.15
Seizure responder rates (50% or more reduction in seizure 
frequency) were 14% in placebo group, 15% in the 50 mg/day 
arm, 31% in the 150 mg/day arm, 40% in the 300 mg/day arm 
and 51% in the 600 mg/day arm. There was trend of better 
Table 1 Summary of randomized, double-blind, placebo-controlled trials with pregabalin
Author Doses used (mg/day) Seizure responder rate (%) Discontinuation rate (%) Most common side effects
French15 50, 150, 300, 600 in BiD doses 15, 31, 40, 51 7, 1.2, 14, 24 Somnolence, dizziness
Arroyo16 150, 600 in TiD doses 14.1, 43.5 10, 18.5 Dizziness, somnolence
Beydoun17 600 in BiD vs TiD doses 43, 49 26, 19 Dizziness, somnolence
Elger18 600 in BID vs 150–600 flexible dose 45.3, 31.3 33, 12 Dizziness, ataxia
Abbreviations: BiD, given in two divided doses; TiD, given in three divided doses.Neuropsychiatric Disease and Treatment 2009:5 409
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efficacy with higher doses. The 150 to 600 mg/day pregabalin 
groups were associated with greater reductions in seizures 
(P  0.0001) and greater responder rates compared with the 
placebo group (P  0.006). However the discontinuation rate 
due to side effects was also higher with higher dosages (5% in 
placebo, 7% in the 50 mg/day group, 1.2% in the 150 mg/day 
group, 14% in the 300 mg/day group, and 24% in the 600 mg/day 
group). Most adverse events were of mild or moderate intensity, 
tended to occur sooner after initiation of pregabalin and resolved 
while patients remained on study treatment. Most common side 
effects were dizziness and somnolence.
Arroyo et al did a dose response study with pregabalin. 
In a multicenter 12-week, double-blind, randomized study in 
refractory partial epilepsy patients they evaluated pregabalin 
150 mg/day vs 600 mg/day given in three divided dose.16 
Pregabalin was significantly more effective than placebo in 
reducing the risk ratio (RR, a simple transformation of the 
seizure data and allows for the use of parametric statistics) in 
both 150 mg/day and 600 mg/day groups (−11.5 [P = 0.0007] 
and −31.4 [P  0.0001], respectively).16
The RR values corresponded to seizure-frequency 
reductions from baseline of 1.8%, 20.6%, and 47.8% for 
placebo, 150 mg/day, and 600 mg/day, respectively. They 
found that pregabalin efficacy was dose-related and more 
patients on pregabalin were responders compared to placebo 
(P  0.0001). Responder rate for the 600 mg/day pregabalin 
group was statistically superior to that of the 150 mg/day 
pregabalin group (P  0.001).
Pregabalin was well tolerated in this study. Adverse 
events were mostly mild or moderate in intensity. Most 
common side effects reported were somnolence, dizziness, 
ataxia, diplopia, and weight gain. The median duration of 
any adverse events was similar among the 600 mg/day pre-
gabalin group (54 days) and the placebo group (55 days) and 
was shortest in the 150 mg/day pregabalin group (28 days). 
The withdrawal rate because of adverse events was higher 
in the 600 mg/day group (18.5% at 600 mg/day vs 10% at 
150 mg/day; 6.2% in the placebo group).
Beydoun et al studied pregabalin given in two vs. three 
divided doses in a multicenter, double-blind, randomized, 
parallel-group, placebo-controlled 12 weeks trial of refractory 
partial epilepsy patients.17 Pregabalin 600 mg/day dose was 
administered in two or three divided doses. Pregabalin resulted 
in significant seizure frequency reductions compared to placebo 
(P  0.0001) (53% for three times a day group vs 44% for twice 
daily group vs 1% increase for placebo). Fifty percent responder 
rates were 49% for three times a day group vs 43% for twice 
daily group compared with 9% for placebo (P  0.001).17
The majority of side effects were mild to moderate in 
intensity in this study. Overall, dizziness was most frequently 
occurring side effects in all three treatment groups and it was 
dose dependent (38% for three times a day and 42% for twice 
daily) than in placebo-treated patients (12%). Other adverse 
events (AEs), eg, somnolence, ataxia, weight gain, amblyopia, 
asthenia, diplopia, and abnormal thinking occurred more fre-
quently in patients randomized to the pregabalin groups. The 
withdrawal rate owing to adverse events was higher in the twice 
daily group than the three times a day group (26% vs 19%).17
Elger et al studied pregabalin in fixed vs flexible dosing in 
randomized, double-blind, placebo-controlled 12 week study 
of patients with partial seizures refractory to AED treatment.18 
Pregabalin was given either in fixed dose of 600 mg/day 
given twice daily, or flexible dose of 150 to 600 mg/day 
given twice daily. Pregabalin resulted in a reduction in seizure 
frequency of 35.4% for the pregabalin flexible-dose group, 
and 49.3% for the pregabalin fixed-dose group compared 
with 10.6% for the placebo group.18 Most adverse events 
were mild to moderate. Overall, dizziness was the most 
frequent side effect in all three treatment groups and was 
dose-dependent (5.3% for the flexible dose group and 13.9% 
for the fixed dose group; placebo 0%). Other side effects seen 
more frequently in the pregabalin-treated group were ataxia, 
asthenia, somnolence, vertigo, and diplopia. The withdrawal 
rate owing to adverse events was higher in the fixed- than 
the flexible-dose group (32.8% vs 12.2%).18
In all these four randomized placebo-controlled parallel 
trials of pregabalin as an add on therapy for partial epilepsy, 
the odds ratio for a 50% reduction in seizure frequency 
was 3.56 (CI 2.60 to 4.87) for pregabalin (all doses pooled) 
relative to placebo.19
The long-term efficacy of pregabalin as add on therapy 
in partial epilepsy was studied in four long term open label 
extension studies of 1480 patients. Majority of patients 
received pregabalin 450 mg/day. Over the last 6 and 
12 months of pregabalin across these studies, proportion of 
seizure freedom ranged from 7.4% to 24.2% and from 4.5% 
to 18.4%. Seizure responder rates were 41% to 60% during 
the subsequent 6, 12, or 24 months.20,21
Postmarketing epilepsy studies
Since the marketing of pregabalin a number of published 
open-label and placebo controlled studies have confirmed 
the efficacy of pregabalin. Selected studies are presented in 
relation to specific aspects of pregabalin.
In a placebo-controlled randomized study of pregabalin in 
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pregabalin fixed dose (600 mg/day twice daily), or pregabalin 
flexible dose (150 and 300 mg/day for 2 weeks each; 450 and 
600 mg/day for 4 weeks each, twice daily) or placebo for 
12 weeks.22 Dosage was adjusted based on tolerability and 
maintained when a 4-week seizure-free period was achieved. 
Both pregabalin regimens significantly reduced seizure fre-
quency compared with placebo, by 35.4%, for flexible dose 
(P = 0.0091) and 49.3% for fixed dose (P = 0.0001) vs 10.6% 
for placebo, and the fixed-dose group was superior to the 
flexible-dose group (P = 0.0337). Most adverse events 
were mild or moderate and incidence of adverse events 
and discontinuations were lower in patients when dosing 
was individualized to optimize efficacy and tolerability. 
Discontinuation rates due to adverse events were higher in 
fixed dose group and discontinuation was earlier than other 
groups (32.8% fixed vs 12.2% flexible group.22
In another trial evaluating cost effectiveness of pregabalin 
to other antiepileptic medications, the cost-effectiveness 
of pregabalin therapy in terms of cost per seizure-free day 
gained or cost per quality-adjusted life-years gained com-
pares favorably with published estimates for other add-on 
antiepileptic medications.23
In analysis of pooled patient data from four short-term 
placebo studies of pregabalin (150 to 600 mg/day) demon-
strates that pregabalin is an effective and well tolerated add-
on treatment for partial seizure with or without secondary 
generalization.24 Weight gain, reported by 5.4% to 17.1% of 
patients across pregabalin dosing groups, was dose-related 
(highest in the 600 mg/day group) and resulted in with-
drawal from study in only 0.74% (6/810, 4 of whom were in 
600 mg/day group) pregabalin-treated subjects. Weight gain 
reached steady state in 85 days.24
Weight gain has been a significant adverse effect with 
pregabalin. In another study evaluating the utility of short 
counseling program to prevent weight gain, showed the 
mean bodyweight increase, compared to baseline, of 2.5 kg 
(SD ± 3.7 kg; median: 2.0 kg) and 4.0 kg (SD ± 4.1 kg; 
median: 4.0 kg; N = 60) at the 3- and 6-month follow-up, 
respectively.25 The body mass index increment was 0.9 
(SD ± 1.3; median: 0.6) and 1.4 (SD ± 1.4; median: 1.3) for 
the 3- and 6-month follow-up, respectively.25
Pregabalin in epilepsy patients 
with intellectual and developmental 
disability
Epilepsy is common in patients with intellectual and devel-
opmental disability (I/DD) and they tend to have medically 
refractory epilepsy, often with multiple seizure types.26 
Pregabalin efficacy and tolerability has been studied in 
institutionalized patients with epilepsy and intellectual and 
developmental disability (I/DD) mostly in a retrospective 
study design.27,28 Huber et al retrospective study of pregabalin 
in 32 institutionalized patients with therapy-resistant epilepsy 
and intellectual disability showed modest efficacy.28 The 
retention rate was 75% after 6 months. Six patients (18.75%) 
were responders (50% seizure reduction). No patient 
was seizure free. Eight patients had side effects that were 
essentially impairing. Weight gain, somnolence, asthenia, 
and ataxia were the most frequent adverse effects. Rare 
adverse events were severe mental slowing and loss of daily 
life capacities on a low dose of pregabalin in one patient 
and increase in auto-aggression in another patient. After 
12 months, the retention rate dropped to 40.6%, the responder 
rate was 25%, and one patient was seizure free.
Modur et al studied efficacy and tolerability of pregabalin 
in a retrospective study of seven institutionalized patients 
with I/DD.27 The primary efficacy measure was the change 
in the median frequency of seizure days per week between 
the baseline (8 weeks prior to initiating pregabalin) and 
treatment (12 weeks of titration and maintenance) periods. 
The mean dose of pregabalin was 293 mg/day (range 
150 to 350 mg/day). Pregabalin was efficacious, resulting 
in a significant reduction in the median frequency of seizure 
days/week between baseline and treatment (1.38 vs 0.50, 
P = 0.018). The 50% responder rate was 71%. The adverse 
effects at last follow-up (mean 13 months) included weight 
gain, myoclonus, and sedation. Though Modur et al study had 
a smaller sample size but their responder rate was better than 
Huber study. The reason for the discrepancy may be that these 
studies had different dosages – mean dose 390 mg/day in 
Huber vs 293 mg/day in Modur. Modur et al studied efficacy 
at the end of 12 weeks of treatment while Huber evaluated 
efficacy at 6 months and 12 months of treatment; thus Huber 
et al had a longer study duration that may account for the 
relatively low responder rate.
In a postmarketing retrospective analysis, efficacy and 
tolerability of pregabalin was studied over 15 months, in 
119 patients from two epilepsy clinics. Forty-six (38.6%) 
patients had discontinued pregabalin, 33% (15/46) of patients 
discontinued pregabalin for lack of efficacy, while 66% 
stopped pregabalin for adverse effects.29 The most common 
adverse effect causing discontinuation was behavioral and 
psychiatric adverse effects, including agitation, irritability, 
and depression (9 patients – 20% of those discontinuing). 
Weight gain was the second most common reason for Neuropsychiatric Disease and Treatment 2009:5 411
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discontinuation (7 patients,15%). The average weight change 
was +12 lb (5.5 kg) (range −8 to +71 lb; 3.6 to 32.3 kg) and 
average weight change per month was 1.1 lb (0.5 kg).29 
Twenty-nine (33%) patients had a 10% increase in weight. 
The median reduction in seizure frequency was 41%. Prega-
balin efficacy postmarketing was similar to that in clinical 
trials. However, behavioral adverse effects and weight gain 
were the most important reasons for discontinuation.
Pregabalin is the latest addition to the armamentarium 
against epilepsy. Its pharmacological and pharmacokinetic 
properties make it favorable for its use in clinical practice. 
Pregabalin’s potent anticonvulsant activity (seizure responder 
rate of 51%) is helpful in its clinical use. In clinical trials 
pregabalin has been found to be highly effective and well 
tolerated as adjunctive therapy for the treatment of patients 
with partial onset seizures with or without secondary gener-
alization. Pregabalin’s predictable oral absorption, lack of 
interaction, lack of protein binding, lack of hepatic metabo-
lism, and linear pharmacokinetics are favorable. However 
weight gain, behavioral adverse effects, and myoclonus 
have to be carefully monitored by the clinicians while using 
pregabalin.
Effect on sleep in epilepsy patients
Sleep problems are a common issue with epilepsy patients 
and lack of sleep can worsen seizures. Pregabalin has been 
reported to enhance NREM sleep and reduces REM sleep in 
rats.30 Similarly in humans it improves sleep quality. In a trial 
of adult patients with partial epilepsy treated with pregabalin 
underwent 24-hour ambulatory polysomnography. Sleep 
quality was assessed with Epworth Sleepiness Scale (ESS) 
before and after 3 months treatment with pregabalin.31 
A significant increase in REM sleep and a decrease of 
stage 2 NREM sleep was noted with pregabalin use. Epworth 
Sleepiness Scale showed a significant increase in the score 
but did not reach the pathological cut-off value (mean ESS 
score 10). The increase in REM sleep may indicate an 
improvement in nocturnal sleep quality while the increase 
of ESS score indicates that daytime somnolence is a minor 
adverse effect of prebalin.31
Pregabalin in other neurological/
psychiatric disorders
Comorbidities are important considerations in epilepsy 
patients in choosing the AED. AEDs are now often used to 
treat other disorders besides epilepsy and their efficacy is 
established in some non-epilepsy disorders both in neurology 
and psychiatry.32 In a randomized controlled 5-week trial of 
pregabalin in diabetic peripheral neuropathic pain, patients 
on doses of 300 or 600 mg/day showed significant improve-
ments in endpoint mean pain score vs placebo (P = 0.0001).33 
Sustained improvements in pain and sleep quality were seen 
as early as week 1. A dose-related response was seen as a 
50% reduction in pain compared to baseline at 46% in the 
300 mg/day arm and 48% in the 600 mg/day arm. Pregabalin 
was well tolerated with a low discontinuation rate.33 This trial 
showed pregabalin’s efficacy in the treatment of diabetic 
peripheral neuropathic pain.
In another randomized controlled 8-week trial of prega-
balin in the treatment of postherpetic neuralgia, pregabalin-
treated patients had significantly greater decreases in pain 
score than placebo (3.60 vs 5.29, P = 0.0001).34 Pain was sig-
nificantly reduced very early in the trial. Similar to the trial in 
diabetic peripheral neuropathy, sleep also improved in patients 
treated with pregabalin compared to placebo (P = 0.0001). 
The side effects were generally mild to moderate.34
More recently pregabalin was studied in fibromyalgia 
in a randomized, controlled 13-week trial.35 Patients in 
all pregabalin groups (300, 450 and 600 mg/day) showed 
statistically significant improvement in endpoint mean pain 
score. Similarly, all patients showed statistically significant 
improvement in assessments of sleep.35 Dizziness and som-
nolence were the most frequently reported adverse events.
Pregabalin has been evaluated for generalized anxiety 
disorder in 4 placebo-controlled clinical trials. Patients 
were randomized to 6 weeks of double-blind treatment with 
pregabalin 400 or 600 mg/day, venlafaxine 75 mg/day, or 
placebo.36 Pregabalin showed significantly greater improve-
ment in anxiety score even at week 1. Pregabalin was 
concluded to be safe, well tolerated, and rapidly efficacious 
across the physical–somatic as well as the emotional symp-
toms of anxiety in primary care and psychiatric settings. 
Pregabalin has been approved in the European Union for 
generalized anxiety disorder.
Pregabalin tolerability
Pregabalin was found to be very well tolerated in the initial 
placebo-controlled adjunctive trials in partial epilepsy. 
The treatment-related adverse events were mild to moderate, 
appeared in the beginning of treatment, and resolved while 
patients remained on study treatment. Most common 
side effects were dizziness, ataxia, somnolence, and diplopia. 
Weight gain and behavioral side effects were not prominent 
in pivotal pregabalin trials. However in postmarketing 
analysis of pregabalin in epilepsy patients, the most com-
mon adverse effects causing discontinuation were behavioral Neuropsychiatric Disease and Treatment 2009:5 412
Arain Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
adverse effects (agitation, irritability, and depression) and 
weight gain. Of note, no systemic side effects have been 
seen with pregabalin but myoclonus has been reported in 
4 patients who developed new onset myoclonus at a dose of 
50 to 600 mg/day.37 Patients had focal or multifocal myoclo-
nus without any EEG changes. Myoclonic jerks significantly 
decreased after dose reduction of pregabalin.37
Place of pregabalin in epilpesy 
therapy
Pregabalin is effective in partial epilepsy, but its efficacy in 
generalized epilepsy is not established. It should be consid-
ered as an early adjunctive therapy in partial epilepsy because 
of its ease of use, linear kinetics and lack of drug-drug inter-
actions.19–21,24,38 Pregabalin’s lack of drug–drug interaction 
makes it a particularly good choice in elderly patients who 
commonly are on multiple medications. In patients with 
hepatic insufficiency pregabalin along with levetiracetam 
and gabapentin are a good choice because of the absence of 
hepatic metabolism. Pregabalin’s efficacy in multiple condi-
tions makes it an earlier choice in epilepsy patients who suffer 
from such conditions. Since anxiety is a common comorbidity 
in epilepsy patients,39 patients with epilepsy and anxiety may 
benefit from pregabalin. Similarly in epilepsy patients with 
diabetic polyneuropathy and fibromyalgia, pregabalin would 
be a very appropriate add-on therapy.
Because of the potential side effect of weight gain 
patients should be counseled about routine exercise and their 
weight should be closely monitored when they are started on 
pregabalin. Similarly patients started on pregabalin should 
also be monitored for behavioral adverse effects, especially 
in epilepsy patients with intellectual and developmental 
disability.
The prescribing information recommends an adult start-
ing dose of 50 mg three times a day or 75 mg twice a day, 
with subsequent escalation by 100 to 150 mg every week up 
to a maximum of 300 mg twice daily. These recommenda-
tions are based on the dose used in pivotal trials. However 
because of clinical experience and evidence from postmar-
keting analyses, the author favors a lower starting dose of 
50 mg twice daily or 75 mg at bedtime because of excessive 
sedation especially in elderly patients, with escalation to 
75 mg twice daily after 1 week if the starting dose is well 
tolerated. In patients at higher risk for behavioral–psychiatric 
adverse effects, the starting dose can even be smaller, at 
50 mg at bedtime. In patients who tolerate pregabalin but 
still have uncontrolled seizures on 300 mg twice a day, the 
author recommends splitting the dose to 200 mg three times 
a day for better efficacy. However three times a day dosing 
may decrease compliance and hence benefits and risks have 
to be weighed.
Overall pregabalin is a good addition to the armamentarium 
against epilepsy. Its reliable absorption, linear kinetics, better 
efficacy, lack of drug–drug interaction, and lack of hepatic 
metabolism make it an attractive adjunctive therapy in control-
ling seizures. Pregabalin monotherapy trials will be needed 
to evaluate it as first-line therapy in new onset epilepsy or for 
conversion monotherapy in less refractory partial epilepsy.
Disclosures
The author has received research grant support from Pfizer 
and has given occasional lectures sponsored by the Pfizer 
speakers bureau.
References
  1.  Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol 
Neurosurg Psychiatry. 1996;61(5):433–443.
  2.  Arain A. Medical therapy of epilepsy. Expert Opin Ther Pat. 
2007;17(8):955–964.
  3.  Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl 
J Med. 2000;342(5):314–319.
  4.  Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: 
a systematic review of their efficacy and tolerability. BMJ. 
1996;313(7066):1169–1174.
  5.  Vartanian MG, Radulovic LL, Kinsora JJ, et al. Activity profile of 
pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 
2006;68(3):189–205.
  6.  Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of 
action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) 
subunit as a target for antiepileptic drug discovery. Epilepsy Res. 
2007;73(2):137–150.
  7.  Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action 
of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium 
channels: inhibition of K+-evoked [3H]-norepinephrine release from 
rat neocortical slices. Synapse. 2002;45(3):171–190.
  8.  Patsalos PN, Perucca E. Clinically important drug interactions in 
epilepsy: interactions between antiepileptic drugs and other drugs. 
Lancet Neurol. 2003;2(8):473–481.
  9.  Harden CL, Leppik I. Optimizing therapy of seizures in women who 
use oral contraceptives. Neurology. 2006;67(12 Suppl 4):S56–S58.
10.  Perucca E. Clinically relevant drug interactions with antiepileptic drugs. 
Br J Clin Pharmacol. 2006;61(3):246–255.
11.  Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction 
studies: lack of effect on the pharmacokinetics of carbamazepine, 
phenytoin, lamotrigine, and valproate in patients with partial epilepsy. 
Epilepsia. 2005;46(9):1407–1413.
12.  May TW, Rambeck B, Neb R, Jurgens U. Serum concentrations of 
pregabalin in patients with epilepsy: the influence of dose, age, and 
comedication. Ther Drug Monit. 2007;29(6):789–794.
13.  Johannessen SI, Tomson T. Pharmacokinetic variability of newer 
antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 
2006;45(11):1061–1075.
14.  Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, 
Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various 
degrees of renal function. J Clin Pharmacol. 2003;43(3):277–283.
15.  French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-
response trial of pregabalin adjunctive therapy in patients with partial 
seizures. Neurology. 2003;60(10):1631–1637.Neuropsychiatric Disease and Treatment 2009:5
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
413
Pregabalin in partial epilepsy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
16.  Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: 
a randomized, double-blind, placebo-controlled, dose-response study 
in adults with partial seizures. Epilepsia. 2004;45(1):20–27.
17.  Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, 
Garofalo EA. Safety and efficacy of two pregabalin regimens for add-on 
treatment of partial epilepsy. Neurology. 2005;64(3):475–480.
18.  Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on 
treatment in patients with partial seizures: a novel evaluation of flexible-
dose and fixed-dose treatment in a double-blind, placebo-controlled 
study. Epilepsia. 2005;46(12):1926–1936.
19.  Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-
resistant partial epilepsy. Cochrane Database Syst Rev. 2008(1):
CD005612.
20.  Ryvlin P, Perucca E, Rheims S. Pregabalin for the management of 
partial epilepsy. Neuropsychiatr Dis Treat. 2008;4(6):1211–1224.
21.  Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial 
seizures. CNS Drugs. 2005;19(3):265–272; discussion 273–264.
22.  Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. 
Epilepsia. 2004;45 Suppl 6:19–27.
23.  Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of add-
on therapy with pregabalin in patients with refractory partial epilepsy. 
Epilepsia. 2008;49(3):431–437.
24.  Gil-Nagel A, Zaccara G, Baldinetti F, Leon T. Add-on treatment with 
pregabalin for partial seizures with or without generalisation: Pooled 
data analysis of four randomised placebo-controlled trials. Seizure. 
2009;18(3):184–192.
25.  Hoppe C, Rademacher M, Hoffmann JM, Schmidt D, Elger CE. 
Bodyweight gain under pregabalin therapy in epilepsy: mitigation by 
counseling patients? Seizure. 2008;17(4):327–332.
26.  Arain A, Shihabuddin B, Niaz F, et al. Epilepsy and the impact of an 
epileptology clinic for patients with mental retardation and associ-
ated disabilities in an institutional setting. Epilepsia. 2006;47(12): 
2052–2057.
27.  Modur PN, Milteer WE. Adjunctive pregabalin therapy in mentally 
retarded, developmentally delayed patients with epilepsy. Epilepsy 
Behav. 2008;13(3):554–556.
28.  Huber B, Bocchicchio M, Feuerbaum E, et al. Efficacy and tolerability 
of pregabalin in patients with difficult-to-treat epilepsy and intellectual 
disability. Epilepsy Behav. 2008;13(2):397–401.
29.  Seeley JM, Mrelashvili D, Gallagher MJ, Arain A, Abou-Khalil B. 
Pregabalin efficacy and tolerability in patients with intractable partial 
seizures. A postmarketing analysis. Epilepsia. 2007;48(s6):320–321.
30.  Kubota T, Fang J, Meltzer LT, Krueger JM. Pregabalin enhances nonrapid 
eye movement sleep. J Pharmacol Exp Ther. 2001;299(3):1095–1105.
31.  Romigi A, Izzi F, Marciani MG, et al. Pregabalin as add-on therapy 
induces REM sleep enhancement in partial epilepsy: a polysomno-
graphic study. Eur J Neurol. 2009;16(1):70–75.
32.  Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: 
relations between mechanisms of action and clinical efficacy. CNS 
Drugs. 2008;22(1):27–47.
33.  Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves 
symptoms of painful diabetic neuropathy: a randomized controlled 
trial. Neurology. 2004;63(11):2104–2110.
34.  Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the 
treatment of postherpetic neuralgia: a randomized, placebo-controlled 
trial. Neurology. 2003;60(8):1274–1283.
35.  Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, 
placebo-controlled, phase III trial of pregabalin in the treatment of 
patients with fibromyalgia. J Rheumatol. 2008;35(3):502–514.
36.  Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Effi-
cacy and safety of pregabalin in the treatment of generalized anxiety 
disorder: a 6-week, multicenter, randomized, double-blind, placebo-
controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 
2006;67(5):771–782.
37.  Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy 
patients with anticonvulsive add-on therapy with pregabalin. Epilepsia. 
2001;42(6):790–792.
38.  Beydoun A, Nasreddine W, Atweh S. Efficacy and tolerability of pregab-
alin in partial epilepsy. Expert Rev Neurother. 2008;8(7):1013–1024.
39.  Mensah SA, Beavis JM, Thapar AK, Kerr MP. A community study 
of the presence of anxiety disorder in people with epilepsy. Epilepsy 
Behav. 2007;11(1):118–124.